Perspective Therapeutics (CATX) Stock Forecast: StockMap's 2-Week Call
CATX stock forecast: StockMap's model makes no two-week call on Perspective Therapeutics after the Nov 19 close: its evidence is split, 3 reasons for and 12 against. Right in 6 of 6 two-week windows on CATX since Aug 21; by chance, a call on the same dates was right 59% of the time.
Perspective Therapeutics last closed at $0.78, +0.00% on the session.
Against the IVW growth benchmark the position is +2.33% over the forecast window.
Perspective Therapeutics' market cap is $94.20M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -18 (too close to call).
Where CATX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
31 daily calls for CATX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Perspective Therapeutics in the 19th percentile on return on equity, where 100 is best.
Perspective Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Perspective Therapeutics as the 283rd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Perspective Therapeutics ranks 142nd of 394 in the group, against a group median of -0.27.